FDA Guidance for Industry: Biosimilarity and Interchangeability: Additional Draft Q&As on Biosimilar Development and the BPCI Act

Title:
FDA Guidance for Industry: Biosimilarity and Interchangeability: Additional Draft Q&As on Biosimilar Development and the BPCI Act
Origin/Publisher:

FDA

Content:
This draft guidance document provides answers to common questions from prospective applicants and other interested parties regarding the Biologics Price Competition and Innovation Act of 2009 (BPCI Act)

Go back